As a result, the parties will work together to advise pharma clients on subject matters pertaining to strategy and planning, market access, policy analysis, and more. .
Numerof & Associates has signed a collaborative services agreement with Koios Enterprises and Consulting. As part of that agreement, Michael L. Ryan, PharmD, Kojos’ founder, will serve as an executive advisor with the healthcare strategy firm.
More specifically, the former Bristol-Myers Squibb (BMS) and Amgen senior executive will work closely with the Numerof team to advise selected pharma clients on strategy and planning, market access, policy analysis, and evidence generation, among other services.
Ryan retired in March from BMS, where he was the SVP in charge of US and worldwide value, access, pricing, and health economics and outcomes research (HEOR) for the company’s $46 billion portfolio. Before joining BMS, he spent 16 years at Amgen, in VP and general manager roles, most recently overseeing US reimbursement, value, and access, and previously owning the P&L and US sales and marketing for nephrology.
“I’ve worked closely with Mike Ryan for more than a decade. His visionary leadership and successful track record in managing market access, pricing, and complex policy challenges across the globe is simply unparalleled,” comments Rita Numerof, PhD, president, Numerof & Associates. “We share the same passion for anticipating where global and regional markets are going, and developing the solutions needed to help companies navigate fundamental change in the face of economic and regulatory pressures. We are also committed to helping industry leaders ensure they can continue to innovate and bring new life-saving therapies to patients.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.